Alex Sapir - 24 Jan 2025 Form 4 Insider Report for Fulcrum Therapeutics, Inc. (FULC)

Role
President & Chief Executive Officer, Director
Signature
/s/ Greg Tourangeau as attorney-in-fact for Alex Sapir
Issuer symbol
FULC
Transactions as of
24 Jan 2025
Net transactions value
$0
Form type
4
Filing time
28 Jan 2025, 16:15:11 UTC
Previous filing
08 Jul 2024
Next filing
04 Feb 2026
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FULC Stock option - Right to Buy Award $0 +582,000 $0.000000 582,000 24 Jan 2025 Common Stock 582,000 $4.16 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on January 24, 2025 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2025, subject to the reporting person's continued service on each such vesting date.

Remarks:

President & Chief Executive Officer